Overview - Tianjin Lisheng Pharmaceutical Co., Ltd. has received drug registration certificates for potassium chloride sustained-release tablets in 0.5g and 0.6g specifications from the National Medical Products Administration [1][2] Drug Information - The potassium chloride sustained-release tablets are classified as chemical drugs and are intended for the treatment and prevention of hypokalemia associated or not associated with metabolic alkalosis [1] - The drug registration numbers are 2025S02514 for 0.5g and 2025S02515 for 0.6g [1] Impact on the Company - The approval of this drug will enhance the company's product line for treating digestive system diseases and improve its market competitiveness [2] - The potassium chloride sustained-release tablets are approved under Category 3 of chemical drugs, which is beneficial for expanding market sales and positively impacting future operating performance [2]

Core Viewpoint - The company, Lifesun Pharmaceutical, has received drug registration certificates from the National Medical Products Administration for its potassium chloride sustained-release tablets in 0.5g and 0.6g specifications, indicating successful approval for market entry [1]. Group 1 - The potassium chloride sustained-release tablets are indicated for the treatment and prevention of hypokalemia with or without metabolic alkalosis [1]. - These tablets are particularly useful for patients who do not respond well to dietary management with potassium-rich foods or reduced diuretic dosage [1].

Core Viewpoint - The company, Lifesun Pharmaceutical, has received drug registration certificates for its potassium chloride sustained-release tablets in two specifications, indicating successful approval for market entry [1] Group 1: Company Developments - Lifesun Pharmaceutical announced the receipt of drug registration certificates from the National Medical Products Administration for potassium chloride sustained-release tablets in 0.5g and 0.6g specifications [1] - The potassium chloride sustained-release tablets are indicated for the treatment and prevention of hypokalemia associated or not associated with metabolic alkalosis, particularly when dietary management or reduced diuretic dosage is ineffective [1]

证券代码：002393 证券简称：力生制药 公告编号：2025-059 天津力生制药股份有限公司 关于药品氯化钾缓释片通过上市许可申请的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 四、对本公司的影响及风险提示 公司该药品通过上市许可申请，将进一步丰富公司治疗消化系统疾病药物产品线， 提高公司市场竞争力。根据国家相关政策，公司产品氯化钾缓释片按化学药品3类批准 生产，可视同通过一致性评价，这将有利于扩大公司产品的市场销售，对公司的未来经 营业绩产生积极影响。由于医药产品的行业特点，各类产品/药品的具体销售情况可能 受到市场环境变化等因素影响，具有较大不确定性，敬请广大投资者注意投资风险。 特此公告。 天津力生制药股份有限公司 二、该药品的基本情况 | 药品名称 | | 氯化钾缓释片 | | | --- | --- | --- | --- | | 剂 | 型 | 片 剂 | | | 规 | 格 | 0.5g | 0.6g | | 注册分类 | | 化学药品 | | | 药品生产企业 | | 天津力生制药股份有限公司 | | | 原药品批准文号 | | 无 ...

Core Viewpoint - The company has received drug registration certificates for two specifications of potassium chloride sustained-release tablets, indicating successful approval for market entry [1] Group 1 - The company announced the receipt of the drug registration certificate for potassium chloride sustained-release tablets in 0.5g specification [1] - The company also received the drug registration certificate for potassium chloride sustained-release tablets in 0.6g specification [1] - Both products have successfully passed the drug market licensing application [1]

证券日报网讯 8月25日晚间，力生制药发布公告称，公司将参加由天津证监局指导、天津上市公司协会 及深圳市全景网络有限公司联合举办的"2025年天津辖区上市公司投资者网上集体接待日活动"。 （编辑 姚尧） ...

证券代码：002393 证券简称：力生制药 公告编号：2025-058 天津力生制药股份有限公司 关于参加2025年天津辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，天津力生制药股份有限公司（以下简称"公司"）将 参加由天津证监局指导、天津上市公司协会及深圳市全景网络有限公司联合举办的"2025年 天津辖区上市公司投资者网上集体接待日活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站（http://rs.p5w.net）； 或关注微信公众号（名称：全景财经）；或下载全景路演APP，参与本次互动交流。活动时 间为2025年9月11日（周四）15:00-17:00。出席本次活动的有公司独立董事方建新先生、财 务总监王家颖先生和董事会秘书马霏霏女士，届时公司高管将在线就公司2025年半年度业 绩、公司治理、发展战略、经营状况等投资者关心的问题，与投资者进行沟通与交流，欢迎 广大投资者踊跃参与。 特此公告。 天津力生制药股份有限公司 董事会 20 ...

Group 1 - The company achieved a revenue of 732 million yuan and a net profit attributable to shareholders of 343 million yuan in H1 2025, representing a year-on-year increase of 235.04% [1] - The significant growth in net profit is primarily due to cash dividends received from Tian Shili Bio, in which the company's wholly-owned subsidiary, Central Pharmaceutical, holds a 12.15% stake, amounting to 303.75 million yuan [1] - The company maintains a gross margin of 59.16% and a net profit margin of 14.25% in H1 2025, reflecting improvements of 3 percentage points and 0.93 percentage points year-on-year, respectively [1] Group 2 - The company has identified over 300 quality projects and is preparing to establish an industrial merger and acquisition fund [2] - In H1 2025, the company invested 60.51 million yuan in R&D, with an investment rate exceeding 8%, resulting in multiple breakthroughs and the approval of three core products [2] - The company has enhanced its marketing and production capabilities, with significant sales growth in various products, including a 14% increase in sales revenue for urokinase injection and a 48% surge in external sales of heparin sodium injection [2]

Core Insights - The company reported a revenue of 732 million yuan for the first half of 2025, a decrease of 1.76% year-on-year, while net profit increased by 235.04% to 343 million yuan [1] - The company focuses on the pharmaceutical health industry, with a product portfolio that includes 296 drugs across 15 categories, and has received 111 patent authorizations [1] - The company is implementing a dual-driven strategy of "industrial operation + capital operation" and is actively engaged in CMO/CDMO services to support the pharmaceutical innovation ecosystem in Tianjin [1] Financial Performance - Revenue for the first half of 2025 was 732 million yuan, down 1.76% from the previous year [1] - Net profit reached 343 million yuan, marking a significant increase of 235.04% year-on-year [1] - The company invested 60.51 million yuan in R&D, representing over 8% of its revenue [2] R&D and Innovation - The company made breakthroughs in R&D, applying for 9 patents and obtaining 2 during the reporting period [2] - It completed the application for 7 generic drugs and achieved approval for 3 core products, including Cefaclor sustained-release tablets and Voriconazole [2] Marketing and Sales Strategy - The company established a "four-wheel" marketing system, focusing on the core product Indapamide to enhance its distribution network in first and second-tier markets [2] - The company adopted a dual strategy of "academic promotion + brand building" to accelerate the market entry of 4 new generic drugs [2] - Retail segment revenue grew rapidly due to enhanced customer engagement through precise brand positioning [2] Business Development - The CMO/CDMO business achieved breakthroughs with the signing of 2 project contracts [3] - The company plans to establish a 1 billion yuan investment fund in collaboration with other financial entities, with an initial investment of 500 million yuan [3] - This investment is expected to optimize the company's business structure and enhance its operational strength [3]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved significant profit growth, with a 235.04% year-on-year increase in net profit attributable to shareholders, reaching 343 million yuan in H1 2025 [4] - The substantial profit increase is primarily due to cash dividends received from a subsidiary, Central Pharmaceutical, amounting to 303.75 million yuan [4] - The company is focusing on deep integration of innovation and industrial resources to drive high-quality development [4] - The projected net profits for 2025-2027 are estimated at 466 million yuan, 291 million yuan, and 331 million yuan respectively, with corresponding EPS of 1.81, 1.13, and 1.28 yuan per share [4] Financial Performance - In H1 2025, the company reported revenues of 732 million yuan and a gross margin of 59.16%, which is an increase of 3 percentage points year-on-year [4] - The net profit margin for H1 2025 was 14.25%, up by 0.93 percentage points year-on-year [4] - The company’s total market capitalization is 6.592 billion yuan, with a circulating market capitalization of 6.403 billion yuan [1] Research and Development - The company has identified over 300 quality projects and invested 60.51 million yuan in R&D in H1 2025, representing an investment rate of over 8% [5] - The company applied for 9 patents and received approval for 3 core products [5] Market Strategy - The company is enhancing its distribution network and product value chain, particularly focusing on its core product, Indapamide [5] - The company is also establishing a 1 billion yuan equity investment fund to strengthen its operational capabilities [4][5]